A sensitive and selective high-performance liquidchromatographic assay for ibuprofen and its major metabolites in biological fluids is described_ To ensure good chromatographic separation the drug and metabolites were in on a gradient elution system and detected with a variable wavelength detector set at 220 nm. A second, more rapid, isocratic system is also described for the detection of only ibuprofen_ 
ibuprofen and its major metabolites (Assay I)_ A second, more rapid assay for ibuprofen alone was also developed (Assay II).
M_4TERIALS AND METHODS

Standards
Ibuprofen, OH-ibuprofen, COOH-ibuprofen, and methyl prednisolone were provided by the Upjohn Company (Kalamazoo, MI, U.S.A.). Tolmetin was provided by McNeil Laboratories (Fort Washington, PA, U.S.A.)
HPLC appanzfus for the simultaneous determination of ibuprofen, OHibwwofen and COOH-ibuprofen in biological samples, Assay I
Due to the more highly polar nature of the two metabolites relative to the parent compound, isocratic elution was found to be unsatisfactory and a gradient system had to be employed_ The apparatus used consisted of two Waters Model 6000A pumps (Waters Assoc., Milford, MA, U_S.A_) controlled by a Model 660 solvent programmer, a Waters variable wavelength detector set at 220 nm and an Omniscribe chart recorder (Houston Instruments). Separation was achieved with a prepacked Whatman column (Whatman, Clifton, NJ, U.S.A.) (25 cm X 4.5 mm I.D., Partisil 10 ODS-3 packing). The eiuents delivered by the two pumps were of the following compositions_ Eluent Ar acetonitrile-water (28:72)_ To each liter of eluent was added 500 yl of phosphoric acid and 500 ~1 of acetone_ Eluent B: acetonitrile-O-05 M monobasic potassium phosphate (50:50). The delivery rate of the mobile phase was 2 ml mm-' and a typical run was performed in the following manner. The column was allowed to come to equilibrium with eluent A. At time zero the sample wasloaded ontothecolumnthrough aWatersloopinjector_After8
x-nin the solvent programmer was switched from these initial conditions to the 'Mm" mode_ Over the next 6 min (i.e. 8-14 min after the injection) the percentage of eluent A in the eluting solvent was reduced from 100% to 0% in a linear manner with respect to time while the percentage of eluent B increased from 0% to 100%. Thus, from 14 min after the injection_ to the termination of the run the eluting solvent was 100% B. Fig. lc graphically represents the change in eluent composition with respect to time_ HPLC apparatus for the determination of ibuprofen in biological samples, Assay II The basic HPLC equipment used for Assay II was similar in all respects to that used in Assay 1. tlowever, due to the isocratic nature of the assay, the solvent delivery system consisted of a single pump_ The mobile phase was methanol-water (70:30) with 1 ml of phosphoric acid added to each liter of eluent. The mobile phase was delivered at a flow-rate of 2.5 ml min-' .
Sample preparation for Assay I
Assay I was primarily used to assay urine samples for unchanged drug and metabolites. A simple clean-up extraction was required before urine samples could be chromatographed A l-ml sample of urine or diluted urine was ad&d to a screw-tipped test tube_ A 100~,cl aliquot of internal standard solution (methylprednisolone 1 mg/ml) was added followed by 1 ml of 1.5 M hydrochloric acid to reduce the pH below 1. Finally, 500 ~1 of water and 10 ml of methylene chloride were added and the tubes were capped and shaken for 20 min. The tubes were then gently centrifuged (250 g, 3 min, Sorvall RC3 centrifuge)_ The lower organic phase was transferred to a clean, dry test tube and was evaporated to dryness under a stream of prepurified nitrogen at 40°C. Samples were reconstituted with 200 ~1 of methanol and lo-30 ~1 of this were injected onto the column.
To enable free and conjugated metabolites to be assayed in the urine, all samples were assayed twice. Free drug and metabolites were assayed as described above. Total drug and metaholites (free plus conjugated) were assayed following alkaline hydrolysis. Hydrolysis was carried out by incubating 1 ml of urine or diluted urine with 500 ~1 of 1 M sodium hydroxide solution for 20 min at room temperature. Following this period the extraction was carried out as described above.
Sample preparation for Assay II
Assay II was primarily used to assay plasma samples for unchanged drug. Plasma samples were subjected to a clean-up extraction before being chromatographed. To 1 ml of plasma in a screw-topped test tube were added 100 ~1 of internal standard soiution (tolmetin, 100 pg/ml internal standard solution).
The samples was acidified with 500 ~1 of 1 M hydrochloric acid and 10 ml of methylene chloride were added_ The tubes were capped, shaken for 10 min and then centrifuged at 1000 g for 5 min to ensure complete phase separation.
The lower, organic layer was transferred to a clean, dry test tube and was evaporated to dryness under a stream of prepurified nitrogen at 40°C. Just prior to analysis the residue was redissolved in 200 ,~l of Assay II eluent and lo-30 ~1 of this sample were loaded onto the column.
Calibration procedure for Assay I
Blank urine was spiked with ibuprofen, OH-ibuprofen and COOH-ibuprofen in the range 5-200 gg ml-' _ The urine samples were subjected to the preparation procedures described above and were chromatographed in the normal manner-Peak heights of ibuprofen, metabolites and internal standard were measured from the resultant chromatograms.
A peak height ratio (peak height of compound divided by peak height of 'internal standard) versus concentration curve was constructed for the parent drug and metabolites. The peak height ratios of unknown samples were compared to this standard curve, corrections being made for any dilutions involved.
Calibmtion procedure for Assay II
Blank plasma was spiked with ibuprofen over the range l-140 pg/ml. Plasma prepared in this way was subjected to the normal extraction and chromatographic procedures. From the chromatograms obtained the ibuprofen:tolmetin peak height ratio was calculated and a calibration curve. relating this ratio to the plasma concentration of ibuprofen .was constructed. Unknown samples were quantified by reference to this standard curve.
RESULTS AND DISCUSSION
-4 typical HPLC trace for Assay I is shown in Fig_ la_ The relative order of peak retention and retention times were: OH-ibuprofen (8.0 min), COOHibuprofen (10.2 min), methylprednisolone (13.6 min) and ibuprofen (21.8 min). No interfering peaks were observed when blank urine was subjected to the assay (Fig_ lb)_ Calibration data (compound peak height ratio versus compound concentration, pg ml-') were best fitted by the power curve described by the equation
where X and Y are concentration and peak height ratio, respectively. The relationship between X and Y was actually linear since S was essentially equal to unity. However, the use of eqn. 1 gave the lowest coefficient of variation of inversely estimated concentrations, apparently as a result of the different weighting of the points. The results of inversely estimating ibuprofen and metabolite concentrations from the calibration data generated from standards prepared over several months are shown in Table I . No systematic bias was observable over the concentration range studied. The intra-day reproducibility of Assay I is good, as is shown in Table II C.V. values were just greater than 10% while the remaining six were less than 10%. Urine spiked with ibuprofen and metabolites at 30 pg/ml was divided into l-ml aliquots and frozen. On each assay day one urine aliquot was thawed and assayed_ The stability of frozen samples and the inter-day reproducibility is shown in Table III . No trend towards sample degradation is seen but, as may have been expected over such a protracted period of time, slightly larger coefficients of variation are observed. The lower limit of detection of Assay II as described for ibuprofen and its metabolites (around 5 pg ml-') was sufficient to enable detection of 1.0% of a 400-mg dose of ibuprofen in 1 1 of urine. For the purposes for which the assay was used this proved to be adequate. If greater sensitivity is desired, extraction from a larger urine volume, or a decrease in internal standard and injection of a larger volume of the final extract would prove satisfactory.
A typical HPLC trace from Assay II is shown in Fig. 2a . The relative order of peak retention and retention times were tolmetin 3.2 min, and ibuprofen 7.7 min. No interfering peaks in blank plasma were observed (Fig. 2b) . Calibration data were again fitted by a power curve described by eqn. 1. A summary of the calibration data obtained from 22 pooled calibration curves is summarized in Table IV . Again no systematic bias was noted over the concentration range studied_ The intra-day reproducibility of Assay II is good as assessed by. assaying six independently prepared plasma samples at three different concentrations (Table V) . The coefficients of variation observed (all less than 10%) are of the same order as those reported by Keams and Plasma spiked with ibuprofen at 30 pg/ml was divided into l-ml aliquots and frozen. On each assay day one of these quality contr@ sampies was thawed and assay&_
The results are presented in Table  VI_ The The applicability of the assays reported in a clinical study has been demonstrated. Fig. 3a presents from 15 subjects after a 400-mg dose of ibuprofen orally_ Assay II as reported here was ideally suited for following these plasma profiles since the concentration range encUuntered over the study was 110-l pg/ml_ It was generally considered to be u~ecessary to lower the assay limits; however, since only about l/lOth of the reconstituted sample was injected on column the theoretical limits of the assay as described could easily be reduced to 0.1 pg/ml, thus making this assay comparable to or better than that of Ali et al_ [9] _ Urinary excretion data from the same study are presented in Fig. 3b to demonstrate the applicability of Assay I_ Urinary recovery as assayed by this new HPLC method is in good agreement with literature values. It should he noted that Assay I is .applicable to plasma samples but that the concentrations of metabolite present are nearly always at the limits of detection.
CONCLUSION
Assays have been developed to quantify ibuprofen or ibuprofen and its major metabolites in biological fluids. Adequate sensitivity and reproducibility of calibration data have been demonstrated_ The applicability of the described assay methods has been shown. In future papers the applications of these assays to biological samples (plasma and urine) obtained in a four-phase clinical study involving ibuprofen wiil he discussed_
